Membrane-permeable C-terminal dopamine transporter peptides attenuate amphetamine-evoked dopamine release

J Biol Chem. 2013 Sep 20;288(38):27534-27544. doi: 10.1074/jbc.M112.441295. Epub 2013 Jul 24.

Abstract

The dopamine transporter (DAT) is responsible for sequestration of extracellular dopamine (DA). The psychostimulant amphetamine (AMPH) is a DAT substrate, which is actively transported into the nerve terminal, eliciting vesicular depletion and reversal of DA transport via DAT. Here, we investigate the role of the DAT C terminus in AMPH-evoked DA efflux using cell-permeant dominant-negative peptides. A peptide, which corresponded to the last 24 C-terminal residues of DAT (TAT-C24 DAT) and thereby contained the Ca(2+)-calmodulin-dependent protein kinase IIα (CaMKIIα) binding domain and the PSD-95/Discs-large/ZO-1 (PDZ)-binding sequence of DAT, was made membrane-permeable by fusing it to the cell membrane transduction domain of the HIV-1 Tat protein (TAT-C24WT). The ability of TAT-C24WT but not a scrambled peptide (TAT-C24Scr) to block the CaMKIIα-DAT interaction was supported by co-immunoprecipitation experiments in heterologous cells. In heterologous cells, we also found that TAT-C24WT, but not TAT-C24Scr, decreased AMPH-evoked 1-methyl-4-phenylpyridinium efflux. Moreover, chronoamperometric recordings in striatum revealed diminished AMPH-evoked DA efflux in mice preinjected with TAT-C24WT. Both in heterologous cells and in striatum, the peptide did not further inhibit efflux upon KN-93-mediated inhibition of CaMKIIα activity, consistent with a dominant-negative action preventing binding of CaMKIIα to the DAT C terminus. This was further supported by the ability of a peptide with perturbed PDZ-binding sequence, but preserved CaMKIIα binding (TAT-C24AAA), to diminish AMPH-evoked DA efflux in vivo to the same extent as TAT-C24WT. Finally, AMPH-induced locomotor hyperactivity was attenuated following systemic administration of TAT-C24WT but not TAT-C24Scr. Summarized, our findings substantiate that DAT C-terminal protein-protein interactions are critical for AMPH-evoked DA efflux and suggest that it may be possible to target protein-protein interactions to modulate transporter function and interfere with psychostimulant effects.

Keywords: Addiction; Dopamine Transporter; Neurotransmitter Transport; Protein Kinases; Protein-Protein Interactions; Scaffold Proteins.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amphetamine / adverse effects
  • Amphetamine / pharmacology*
  • Animals
  • Benzylamines / pharmacology
  • Cell-Penetrating Peptides / metabolism
  • Cell-Penetrating Peptides / pharmacology*
  • Central Nervous System Stimulants / adverse effects
  • Central Nervous System Stimulants / pharmacology*
  • Corpus Striatum / metabolism*
  • Dopamine / metabolism*
  • Dopamine Plasma Membrane Transport Proteins / pharmacokinetics
  • Dopamine Plasma Membrane Transport Proteins / pharmacology*
  • Humans
  • Male
  • Mice
  • Motor Activity / drug effects
  • PDZ Domains
  • Protein Kinase C-alpha / antagonists & inhibitors
  • Protein Kinase C-alpha / metabolism
  • Protein Kinase Inhibitors / pharmacology
  • Sulfonamides / pharmacology

Substances

  • Benzylamines
  • Cell-Penetrating Peptides
  • Central Nervous System Stimulants
  • Dopamine Plasma Membrane Transport Proteins
  • Protein Kinase Inhibitors
  • Sulfonamides
  • KN 93
  • Amphetamine
  • Prkca protein, mouse
  • Protein Kinase C-alpha
  • Dopamine